Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Por um escritor misterioso
Descrição
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
Prostate cancer - InDepth - SmartEngage
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
Nubeqa Delays Prostate Cancer Progression in Resistant Prostate
Cells, Free Full-Text
Abiraterone plus prednisone added to androgen deprivation therapy
Focus on Transitional Disease: A Critical Interval to Delay
Darolutamide and Survival in Metastatic, Hormone-Sensitive
ASCO GU 2022: A Randomized, Controlled, Phase 3 Study of
PDF) Safety and tolerability of long-term treatment with
ARASENS: Darolutamide Plus ADT and Docetaxel May Become New
Prostate cancer Nature Reviews Disease Primers
Hormonal therapies for advanced prostate cancer linked to a higher
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
Prostate Cancer Treatment (PDQ®) - PDQ Cancer Information
de
por adulto (o preço varia de acordo com o tamanho do grupo)
